BioSpace News Archive

Bayer today announced that it has entered into an agreement to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc.

Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today it will give a presentation at the 2021 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting , which is being held virtually from June 8-11, 2021.

Newly released iTero Workflow 2.0 software features include faster scanning, improved visualization, and enhanced patient communication tools that help increase practice efficiency, support better clinical diagnosis, and drive patient engagement for treatment acceptance. Available in Q3’21 on the iTero Element 5D imaging system*, a new auto-upload feature will streamline Invisalign case submissions by enabling intraoral color scan images to be used in place of traditional intraoral photos.

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics (DTx) market, announced today that the company plans to participate in the upcoming Stifel 2021 Virtual Cross Sector Insight Conference.

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that as of 2021, Arena received an MSCI ESG Rating of “A.” MSCI ESG Research provides MSCI ESG Ratings on global public and a few private companies on a scale of AAA (leader) to CCC (laggard),

PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating technology, today announced the protocol amendment to expand its Phase 2 VERSATILE-002 study to include patients, in an additional arm, who have failed prior checkpoint inhibitor (CPI) therapy (CPI refractory patients).

The studies underscore the potential for real-world data to advance cancer care, while showcasing Syapse’ unparalleled data analytics and insights capabilities.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel naturally occurring medicines to improve quality of life for cancer patients, and MagicMed Industries (“MagicMed”), a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine

Consistent technological progresses in treatment administered to patients with muscular dystrophy are fueling the demand for non-hormonal steroid modulators in the market

The implication of cardiac restoration systems involves the left ventricular restoration and mitral valve restoration.